Blood vessel maturation in retinoblastoma tumors: Spatial distribution of neovessels and mature vessels and its impact on ocular treatment

Investigative Ophthalmology and Visual Science

Volumn 50, Issue 3, 2009, Pages 1020-1024

  Piña, Yolanda ^a   Boutrid, Hinda ^a   Schefler, Amy ^a   Dubovy, Sander ^a   Feuer, William ^a   Jockovich, Maria Elena ^a   Murray, Timothy G ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLOOD VESSEL; CONTROLLED STUDY; ENUCLEATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETINOBLASTOMA; RISK FACTOR; TUMOR LOCALIZATION; ANIMAL; COMPARATIVE STUDY; DISEASE MODEL; FEMALE; FLUORESCENCE MICROSCOPY; FLUORESCENT ANTIBODY TECHNIQUE; INFANT; MALE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PRESCHOOL CHILD; RETINA TUMOR; TRANSGENIC MOUSE; VASCULARIZATION;

ACTIN; ANGIOGENESIS INHIBITOR; BIOLOGICAL MARKER; CELL SURFACE RECEPTOR; COLLAGEN TYPE 4; ENG PROTEIN, HUMAN; LEUKOCYTE ANTIGEN;

ACTINS; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIGENS, CD; BIOLOGICAL MARKERS; BLOOD VESSELS; CHILD, PRESCHOOL; COLLAGEN TYPE IV; DISEASE MODELS, ANIMAL; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; INFANT; MALE; MICE; MICE, TRANSGENIC; MICROSCOPY, FLUORESCENCE; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, CELL SURFACE; RETINAL NEOPLASMS; RETINOBLASTOMA;

EID: 62649116511     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.08-2654     Document Type: Article

References (34)

1. Tamboli A, Podgor MJ, Horm JW. The incidence of retinoblastoma in the United States: 1974 through 1985. Arch Ophthalmol. 1990;108:128-132.
2. Pendergrass TW, Davis S. Incidence of retinoblastoma in the United States. Arch Ophthalmol. 1980;98:1204-1210.
3. Abramson DH, Beaverson KL, Chang ST, Dunkel IJ, McCormick B. Outcome following initial external beam radiotherapy in patients with Reese-Ellsworth group Vb retinoblastoma. Arch Ophthalmol. 2004;122:1316-1323.
4. Khelfaoui F, Validire P, Auperin A, et al. Histopathologic risk factors in retinoblastoma: a retrospective study of 172 patients treated in a single institution. Cancer. 1996;77:1206-1213.
5. Shields CL, Shields JA, Baez KA, Cater J, De Potter PV. Choroidal invasion of retinoblastoma: metastatic potential and clinical risk factors. Br J Ophthalmol. 1993;77:544-548.
6. Rouic LL, Aerts I, Levy-Gabriel C, et al. Conservative treatments of intraocular retinoblastoma. Ophthalmology. 2008;115(8):1405-1410.
7. Finger PT, Harbour JW, Karcioglu ZA. Risk factors for metastasis in retinoblastoma. Surv Ophthalmol. 2002;47:1-16.
8. Shields CL, Shields JA, Baez K, Cater JR, De Potter P. Optic nerve invasion of retinoblastoma: metastatic potential and clinical risk factors. Cancer. 1994;73:692-698.
9. Honavar SG, Singh AD, Shields CL, et al. Postenucleation adjuvant therapy in high-risk retinoblastoma. Arch Ophthalmol. 2002;120:923-931.
10. Chantada GL, Dunkel IJ, de Davila MT, Abramson DH. Retinoblastoma patients with high risk ocular pathological features: who needs adjuvant therapy? Br J Ophthalmol. 2004;88:1069-1073.
11. Chantada GL, Casco F, Fandino AC, et al. Outcome of patients with retinoblastoma and postlaminar optic nerve invasion. Ophthalmology. 2007;114:2083-2089.
12. Rosenblatt MI, Azar DT. Anti-angiogenic therapy: prospects for treatment of ocular tumors. Semin Ophthalmol. 2006;21:151-160.
13. Stitt AW, Gardiner TA. Anti-angiogenic therapy for uveal melanoma: more haste, less speed. Br J Ophthalmol. 2002;86:368-369.
14. Yang H, Grossniklaus HE. Combined immunologic and anti-angiogenic therapy reduces hepatic micrometastases in a murine ocular melanoma model. Curr Eye Res. 2006;31:557-562.
15. Clark AF, Mellon J, Li XY, et al. Inhibition of intraocular tumor growth by topical application of the angiostatic steroid anecortave acetate. Invest Ophthalmol Vis Sci. 1999;40:2158-2162.
16. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003;3:401-410.
17. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest. 2003;111:1287-1295.
18. Jockovich ME, Murray TG, Escalona-Benz E, Hernandez E, Feuer W. Anecortave acetate as single and adjuvant therapy in the treatment of retinal tumors of LH(BETA)T(AG) mice. Invest Ophthalmol Vis Sci. 2006;47:1264-1268.
19. Jockovich ME, Bajenaru ML, Piña Y, et al. Retinoblastoma tumor vessel maturation impacts efficacy of vessel targeting in the LH-(BETA)T(AG) mouse model. Invest Ophthalmol Vis Sci. 2007;48:2476-2482.
20. Windle JJ, Albert DM, O'Brien JM, et al. Retinoblastoma in transgenic mice. Nature. 1990;343:665-669.
21. Laitinen L. Griffonia simplicifolia lectins bind specifically to endothelial cells and some epithelial cells in mouse tissues. Histochem J. 1987;19:225-234.
22. Nehls V, Drenckhahn D. Heterogeneity of microvascular pericytes for smooth muscle type alpha-actin. J Cell Biol. 1991;113:147-154.
23. Tanaka F, Otake Y, Yanagihara K, et al. Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody. Clin Cancer Res. 2001;7:3410-3415.
24. Jockovich ME, Pina Y, Alegret A, Cebulla C, Feuer W, Murray TG. Heterogeneous tumor vasculature in retinoblastoma: implications for vessel targeting therapy. Retina. 2008;28:S81-S86.
25. Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med. 1995;333:1757-1763.
26. Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003;9:653-660.
27. Darland DC, D'Amore PA. Blood vessel maturation: vascular development comes of age. J Clin Invest. 1999;103:157-158.
28. Gee MS, Procopio WN, Makonnen S, Feldman MD, Yeilding NM, Lee WM. Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy. Am J Pathol. 2003;162:183-193.
29. Dor Y, Djonov V, Abramovitch R, et al. Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J. 2002;21:1939-1947.
30. McCarty MF, Liu W, Fan F, et al. Promises and pitfalls of antiangiogenic therapy in clinical trials. Trends Mol Med. 2003;9:53-58.
31. Reinmuth N, Liu W, Jung YD, et al. Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival. FASEB J. 2001;15:1239-1241.
32. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res. 2000;60:1388-1393.
33. Scehnet JS, Jiang W, Kumar SR, et al. Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion. Blood. 2007;109:4753-4760.
34. Piña YC, Cebulla CM, Murray TG, et al. Blood vessel maturation in human uveal melanoma: spatial distribution of neovessels and mature vasculature. Ophthalmic Res. In press.